Pfizer and Valneva Seek Approval for Lyme Vaccine After Phase 3 Trial

Lyme disease vaccine 70 percent effective, Pfizer says

If approved by regulators, it would be the only vaccine for humans against Lyme disease.

Pfizer Says Lyme Vaccine Missed Trial Target, Will Still Seek Approval

Pfizer and its partner Valneva said on March 23 that their experimental Lyme disease vaccine did not meet the target in a clinical trial, but the results were strong enough that the firms will seek regulatory approval for the shot. The vaccine, known as LB6V, was about 75 percent efficacious in reducing confirmed Lyme in recipients, compared with placebo recipients, the companies said. The efficacy was measured one day after the fourth vaccine d…

Lyme disease vaccine 70 percent effective: Pfizer

Pfizer and Valneva's Lyme disease vaccine shows 70% effectiveness in phase 3 trial. If approved, it would be the first human vaccine for Lyme disease.

Pfizer's Lyme disease vaccine shows 70% efficacy despite trial shortfall

Pfizer wants to fill a 20-year void in human Lyme disease vaccines, but must win over regulators under a vaccine-skeptical administration

Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results

The partners said the shot produced “clinically meaningful” efficacy despite missing its main study objective, a finding they blamed on a lower-than-expected rate of infections during the trial.

Pfizer’s Lyme vaccine shows efficacy, but misses key statistical hurdle - The Boston Globe

The vaccine could represent a weapon for preventing Lyme, a bacterial infection carried by ticks that is diagnosed and treated in an estimated 476,000 people in the US each year.